NCT04624984

PD-1 Inhibitor or PD-1 Inhibitor Plus GVD for Relapsed/Refractory CHL

PD-1 Inhibitor or PD-1 Inhibitor Plus GVD(Gemcitabine, Vinorelbine and Doxorubicin Liposome) Regimen for Relapsed/Refractory Classical Hodgkin Lymphoma (R/R CHL): a Single Arm, Open Label, Phase II Study

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 42 (estimated)
• Sponsor: Sun Yat-sen University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This phase 2 trial studies the efficacy and safety of PD-1 inhibitor monotherapy or PD-1 inhibitor with GVD (Gemcitabine, Vinorelbine and Doxorubicin Liposome) regimen for relapsed or refractory classical Hodgkin lymphoma (CHL) patients who failed the first-line induction therapy.

Conditions

• Classical Hodgkin Lymphoma
• Refractory or Relapsed Classical Hodgkin Lymphoma

Interventions

Type	Name	Description
DRUG	PD-1 inhibitor	PD-1 Inhibitor, intravenous drip, d1.
DRUG	PD-1 inhibitor, gemcitabine, vinorelbine and doxorubicin liposome	PD-1 Inhibitor, intravenous drip, d1; Gemcitabine, 1000mg/m2, intravenous drip, d1,d8; Vinorelbine, 50mg/m2, PO, d1,d8; Doxorubicin Liposome, 30mg/m2, intravenous drip, d1;

Timeline

• Start date: 2021-04-01
• Primary completion: 2025-04-01
• Completion: 2025-04-01
• First posted: 2020-11-12
• Last updated: 2022-05-09

Locations

3 sites across 1 country: China